2 results
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.
Approved WMOCompleted
Primary Objectives- To evaluate disease related characteristics in patients with different vulvar conditions compared to healthy volunteers - To evaluate the variability of the selected biomarkers between subjects, and within subjects over time.…